Switching from Transdermal Drugs: An Observational "N of 1" Study of Fentanyl and Buprenorphine

Journal of Pain and Symptom Management

Volumn 34, Issue 5, 2007, Pages 532-538

  Mercadante, Sebastiano ^a,c   Porzio, Giampiero ^d   Fulfaro, Fabio ^b   Aielli, Federica ^d   Verna, Lucilla ^d   Ficorella, Corrado ^d   Casuccio, Alessandra ^b   Riina, Salvatore ^a   Intravaia, Giuseppe ^a   Mangione, Salvatore ^c  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Palliative Medicine Teaching   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Cancer pain; opioid switching; transdermal buprenorphine; transdermal fentanyl

Indexed keywords

BUPRENORPHINE; FENTANYL; MORPHINE; OPIATE;

ADULT; AGED; ANALGESIA; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONFUSION; CONSTIPATION; DROWSINESS; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HUMAN; LUNG CANCER; MALE; MELANOMA; NAUSEA; PAIN ASSESSMENT; PROSPECTIVE STUDY; SYMPTOM; TREATMENT OUTCOME; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN MEASUREMENT; PAIN, INTRACTABLE; PROSPECTIVE STUDIES;

EID: 35449007161     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2007.01.006     Document Type: Article

References (13)

1. World Health Organization. Cancer pain relief (1986), World Health Organization, Geneva
2. Mercadante S. Transdermal buprenorphine in cancer pain: a renewed therapeutic opportunity. Support Palliat Cancer Care 2 3 (2006) 117-122
3. Atkinson R., Schofield P., and Mellor P. The efficacy in sequential use of buprenorphine and morphine in advanced cancer pain. In: Doyle D. (Ed). Opioids in the treatment of cancer pain (1990), Royal Society of Medicine, London 81-87
4. Kogel B., Christoph T., Strassburger W., and Friderichs E. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain 9 (2005) 599-611
5. Christoph T., Koegel B., Schiene K., et al. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507 (2005) 87-98
6. Mercadante S., Villari P., Ferrera P., et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 32 (2006) 175-179
7. Ahmedzai S., and Brooks D. TTS-Fentanyl Comparative Trial Group. Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 13 (1997) 254-261
8. Donner B., Zenz M., Tryba M., and Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 64 (1996) 527-534
9. Mercadante S., Ferrera P., and Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer 15 4 (2007) 441-444
10. Likar R., and Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg 100 (2005) 781-785
11. Sittl R., Griessinger N., and Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Therap 25 (2003) 150-168
12. Schriek P. Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases. Support Care Cancer 12 (2004) 882-884
13. Sittl R., Likar R., and Nautrup B. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and non cancer pain: results of a retrospective cohort study. Clin Ther 27 (2005) 225-237